This prospective clinical observational study aims to construct a metabolite database specifically for gastric cancer patients using metabolomics technology. It seeks to develop and validate metabolic biomarkers for early diagnosis, prognosis, and prediction of recurrence and metastasis in gastric cancer, thereby a establishing safe, convenient, and highly sensitive method for early screening and prognostic prediction.
Study Type
OBSERVATIONAL
Enrollment
250
Ruijin hospital Shanghai Jiaotong University, School of Medicine , Shanghai, Shanghai 200025
Shanghai, China
RECRUITINGOverall survival
The time from the start of treatment to death due to any cause.
Time frame: 3 years
Disease-Free Survival
Disease-Free Survival (DFS) refers to the length of time after primary treatment for a disease during which the patient remains free of certain signs or symptoms of the disease. It is typically measured from the start of treatment until the first recurrence or relapse of the disease.
Time frame: 3 years
Hazard Ratio
The hazard ratio is a measure of the relative risk of an event occurring in one group compared to another group. It is used to quantify the difference in the rate at which events occur between two groups, typically a treatment group and a control group.
Time frame: 3 years
Positive Predictive Value
The Positive Predictive Value (PPV) indicates how likely it is that a person actually has the disease if the test result is positive.
Time frame: 3 years
Negative Predictive Value
The Negative Predictive Value (NPV) indicates how likely it is that a person does not have the disease if the test result is negative.
Time frame: 3 years
Assessment of Important Metabolic Biomarkers
This outcome measure is intended to identify important metabolic biomarkers that are highly statistically associated with the prognosis of gastric cancer, such as OS, DFS, etc., given different time frames.
Time frame: 3 years
Recurrence Rate
Time frame: 3 years
Cancer-Related Mortality
Time frame: 3 years
Time to Recurrence and Metastasis and Specific Sites
Time frame: 3 years
Distant Metastasis Rate
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.